3 RD ESO-ESMO-RCE PRECEPTORSHIPS & ClINICAl UPDATE ON RARE ADUlT SOlID CANCERS. 1-3 December 2018 Milan, Italy COURSES AND SEMINARS

Transcription

1 3 RD ESO-ESMO-RCE PRECEPTORSHIPS & ClINICAl UPDATE ON RARE ADUlT SOlID CANCERS 1-3 December 2018 Milan, Italy Chairs: J.Y. Blay, FR P.G. Casali, IT R. Stahel, CH Held in collaboration with In the framework of COURSES AND SEMINARS

2 INTRODUCTION Rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. This Course is aimed at dealing with them on an annual basis with the ultimate goal to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence. This course has been conceived in the context of the European Reference Network on Rare Adult Solid Cancers (EURACAN) and the Joint Action on Rare Cancers of the European Union (JARC). The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with the networking activities of EURACAN and the networking educational efforts that are ongoing within EURACAN, JARC and Rare Cancers Europe. The RARECARE project provided a definition and a list of rare cancers, the following being the 10 families of rare adult solid cancers: Rare skin cancers & non-cutaneous melanoma Rare thoracic tumors Rare female genital cancers Neuroendocrine tumors Endocrine gland tumors Sarcomas Digestive rare cancers Rare urological and male genital tumors Central nervous system neoplasms Head & neck cancers format The third edition of this joint initiative, which involves ESO, ESMO and Rare Cancers Europe, will combine: Day 1 - Parallel Preceptorships on the majority of rare adult solid cancers. Participants will be invited to select 3 preceptorships they would like to attend. Day 2 and 3 - Clinical updates on the main innovations from the 10 families of rare adult solid cancers. Preceptorships have been conceived by looking at at the educational needs of clinical oncologists willing to open up to rare adult solid cancers as well as patient advocates. They will be multidisciplinary and clinically oriented. The Clinical update sessions are designed to address the needs of oncologists wanting to catch up with the advancements in the treatment of rare adult solid cancers. Attendees may select whether to attend all three days or only the 2-day Clinical Update.

3 INVITED faculty M. Angi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE J.Y. Blay, Centre Léon Bérard, Lyon, FR A. Berruti, ASST Spedali Civili, Brescia, IT J. Capdevila, Vall d'hebron University Hospital, Barcelona, ES P.g. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT f. De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT A.P. Dei Tos, Azienda ULSS9, Treviso, IT f. De lorenzo, European Cancer Patient Coalition, Brussels, BE M. Deraco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT N. fazio, Istituto Europeo di Oncologia, Milan, IT M. garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT N. girard, Hopital Louis Pradel, Bron, FR J.A. gietema, University Medical Center, Groningen, NL R. glynne-jones, Mount Vernon Centre for Cancer Treatment, London, UK C. grau, Aarhus University Hospital, Aarhus, DK A. gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT C. lebbé, Hopital St. Louis, Paris, FR l. licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT D. lorusso, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT V. Mazzaferro, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT K. Newbold, The Royal Marsden NHS Foundation Trust, London, UK N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT U. Pastorino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT f. Peccatori, European School of Oncology, Milan, IT f. Raspagliesi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT I. Ray-Coquard, Centre Léon Bérard, Lyon, FR J. Sacco, The Clatterbridge Cancer Centre, Liverpool, UK M. Seckl, Hammersmith Campus, London, UK C. Simon, Université de Lausanne, CHUV Lausanne, CH R. Soffietti, AOU San Giovanni Battista, Torino, IT S. Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT R.A. Stahel, Cancer Center University Hospital, Zurich, CH D. Talbot, Oxford University Hospital, Oxford, UK A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT M. Van den Bent, Erasmus MC Cancer Institute, Rotterdam, NL M. wartenberg, Sarcoma Patients EuroNet, Wölfersheim, DE

4 PROgRAMME PRECEPTORSHIPS ON RARE ADULT SOLID CANCERS Saturday, 1 December :30 Registration and coffee entry 8:50 Welcome P.G. Casali, IT INTRODUCTION (plenary) 9:00 Epidemiology and rare cancer networking A. Trama, IT 9:30 The pathologic diagnosis A.P. Dei Tos, IT 10:00 Clinical decision making in RC P.G. Casali, IT Coffee break PARALLEL SESSIONS BREAKOUT PRECEPTORSHIP 1 (11:00-13:00) 11:00 Sarcomas S. Bielack, GR - J.Y. Blay, FR P.G. Casali, IT - A. Gronchi, IT 11:00 Rare urogenital cancers J.A. Gietema, NL - N. Nicolai, IT 11:00 Digestive rare cancers V. Mazzaferro, IT - F. De Braud, IT R. Glynne-Jones, UK Lunch BREAKOUT PRECEPTORSHIP 2 (14:00-16:00) 14:00 Rare female genital cancers D. Lorusso, IT - I. Ray-Coquard, FR F. Raspagliesi, IT - M. Seckl, UK 14:00 Rare thoracic cancers R.A. Stahel, CH - M. Garassino, IT N. Girard, FR - U. Pastorino, IT 14:00 Rare skin tumors and uveal melanoma C. Lebbé, FR - L. Licitra, IT M. Angi, IT - J. Sacco, UK Coffee break BREAKOUT PRECEPTORSHIP 3 (16:30-18:30) 16:30 CNS tumors R. Soffietti, IT - M. van den Bent, NL 16:30 Neuroendocrine tumors D. Talbot, UK - V. Mazzaferro, IT 16:30 Head and neck cancers w/ Thyroid cancer K. Newbold, UK - J. Capdevila, ES C. Simon, CH

5 CLINICAL UPDATE ON RARE ADULT SOLID CANCERS Sunday, 2 December :30 Registration 9:00 Welcome from ESO and ESMO F. Peccatori IT - R.A. Stahel, CH UPDATE ON RARE THORACIC CANCERS Moderators: M. Garassino IT - R.A. Stahel CH 9:10 Mesothelioma R.A. Stahel, CH 9:30 Thymic tumors N. Girard, FR 9:50 Discussion UPDATE ON NEUROENDOCRINE TUMORS Moderators: D. Talbot, UK - F. De Braud IT 10:10 Thoracic neuroendocrine tumors D. Talbot, UK 10:30 Gastroenteropancreatic neuroendocrine tumors N. Fazio, IT 10:50 Discussion 11:10 Coffee break UPDATE ON DIgESTIVE RARE CANCERS Moderators: R. Labianca, IT - V. Mazzaferro, IT 11:40 Biliary tumors F. de Braud, IT 12:00 Anal carcinoma R. Glynne-Jones, UK 12:20 Peritoneal mesothelioma & pseudomyxoma peritonei M. Deraco, IT 12:40 Discussion 13:00 Lunch UPDATE ON CNS TUMORS Moderators: R. Soffietti, IT - M. van den Bent, NL 14:00 Gliomas R. Soffietti, IT 14:20 Rare CNS tumors M. van den Bent, NL 14:40 Discussion UPDATE ON SARCOMAS Moderators: P.G. Casali, IT - A. Gronchi, IT 15:00 Adult soft tissue sarcomas P.G. Casali, IT 15:20 GIST J.Y. Blay, FR 15:40 Ewing sarcoma and Osteosarcoma S. Bielack, DE 16:00 Rare bone sarcomas S. Stacchiotti, IT 16:20 Discussion 16:30 Coffee break

6 UPDATE ON RARE UROgENITAl CANCERS Moderators: J.A. Gietema, NL - N. Nicolai, IT 17:00 Testicular cancer J.A. Gietema, NL 17:20 Discussion UPDATE ON RARE female genital CANCERS Moderators: D. Lorusso, IT - F. Peccatori, IT 17:30 Non-epithelial ovarian tumors I. Ray-Coquard, FR 17:50 Trophoblastic tumors M. Seckl, UK 18:10 Discussion Monday, 3 December 2018 UPDATE ON RARE SKIN TUMORS & UVEAl MElANOMA Moderators: M. Angi, IT - C. Lebbé, FR 9:00 Uveal melanoma M. Angi, IT 9:20 Merkel cell carcinoma C. Lebbé, FR 9:40 Discussion UPDATE ON HEAD & NECK CANCERS Moderators: C. Grau, DK - L. Licitra, IT 10:00 Laryngeal & hypopharyngeal carcinoma L. Licitra, IT 10:20 Oropharyngeal carcinoma C. Grau, DK 10:40 Coffee break 11:00 Nasopharyngeal carcinoma & sinonasal cancers L. Licitra, IT 11:20 Salivary gland tumors L. Licitra, IT 11:40 Discussion UPDATE ON ENDOCRINE gland TUMORS Moderator: L. Licitra, IT 12:00 Adrenal cancer A. Berruti, IT 12:20 Thyroid cancer J. Capdevila, ES 12:40 Discussion 13:00 Lunch RARE CANCERS IN EUROPE Moderators: P.G. Casali IT - F. De Lorenzo IT - M. Wartenberg DE 14:00 Session to be decided 15:30 Closing remarks, with a view to networking P.G. Casali, IT

7 ORgANISINg SECRETARIAT European School of Oncology Rare Tumours Programme c/o Fondazione IRCCS Istituto Nazionale dei Tumori Via G. Venezian, Milan - Italy Fax raretumours@eso.net general INfORMATION VENUE Fondazione Cariplo Conference Center Via Romagnosi, 8 Milan, Italy REgISTRATION Preceptorship day: participants are requested to select one preceptorship in each of the three indicated breakout slots (form to be sent together with registration form) PATIENT ADVOCATES will be selected by Rare Cancers Europe. For information rarecancerseurope@esmo.org REgISTER ONlINE AT Early (by 31 October) Registration fee (full participation rate - 3 days) EUR 250 Club ESO and ESMO Members (full participation rate) EUR 200 Registration fee (Clinical Update - 2 nd and 3 rd day) EUR 200 Club ESO and ESMO Members (Clinical Update) EUR 160 late (from 1 November) EUR 300 EUR 250 Rates are indicated in Euro and include VAT. Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme. ACCREDITATION Application for CME recognition will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and to the Italian CME accreditation system. EACCME credits are recognised by the American Medical Association towards the Physician s Recognition Award (PRA). Information on the status of the applications can be obtained from the organising Secretariat.

8 IMPORTANT DEADlINES TRAVEL GRANTS: 1 October 2018 EARLY REGISTRATION: 31 October 2018 LATE REGISTRATION: from 1 November 2018 CANCEllATION Of REgISTRATION OR REPlACEMENT Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee minus handling charges of EUR 100 will be refunded within two months from notification, provided that the cancellation is received by ESO before 9 November. Communication of replacements will be possible up until 15 November. BADgE The badge is the only official evidence of registration and should be worn at all times during the event. INSURANCE The organisers bear no responsibility for untoward events in relation to the participation during the Course. Participants are advised to take out their own personal and travel insurance. OffICIAl language The official language will be English. No translation will be provided. TRAVEl grants (for PHYSICIANS AND full PARTICIPATION ONlY) Travel grants are given for full participation (three day course) on a competitive basis thanks to the support of Rare Cancers Europe. Priority will be given to younger candidates and low/middle income Countries. To submit the Travel grant application please complete the online form and upload your Curriculum vitae and motivation letter by 1st October. All applicants will be contacted by 15th October. Those applicants who are not selected for a grant will still be able to register with the early rate fee (deadline: 31st October). Successful Travel Grant applicants coming from the following countries will receive: Italy Southern and western Europe Northern, Central and Eastern Europe Other and overseas 500 (plus free registration) 700 (plus free registration) 800 (plus free registration) 1000 (plus free registration) ACKNOwlEDgEMENT ESO wishes to express its gratitude to fondazione Cariplo - Iniziative Patrimoniali S.p.A. for their support in hosting the course in its premises

9 REGISTRATION FORM - PRECEPTORSHIPS & CLINICAL UPDATE ON RARE ADULT SOLID CANCERS, 1-3 December 2018, Milan, Italy Please fill in this form in block capitals and send by the deadline to: European School of Oncology Via Turati, Milan, Italy Marina Fregonese Fax: raretumours@eso.net Participant s details Dr. Prof. Mr. Mrs Family name First name Organisation Department Street Zip Code Town Country Phone Fax Mobile Date of birth Birth place (town and country) Profession Specialisation Main field VAT number (Compulsory for self-employed persons) Fiscal code (Italian residents only) Are you an ESMO Member? YES NO If YES: Membership ID: Expire date (DD/MM/YYYY): If your invoice details are different to those above, please complete the following section: Invoice contact details Address Phone VAT number (Compulsory for companies or self-employed persons) Fiscal code (Italian residents only) Registration fees Rates are indicated in Euro and include VAT. Early Late (by 31 October) (from 1 November) Registration fee (full participation rate - 3 days) EUR 250 EUR 300 Club ESO Members and ESMO Members (full participation rate) EUR 200 EUR 300 Registration fee Clinical Update (2 nd and 3 rd day only) EUR 200 EUR 250 Club ESO Members and ESMO Members (Clinical Update) EUR 160 EUR 250 Payment details The registration is processed when payment accompanies the form (credit card details or copy of bank transfer) Visa/Mastercard Card Number / / / Expiry date / CV2 code Holder s name: and signature BANK TRANSFER with no cost to the beneficiary (please provide a copy of the bank transfer): Bank: Banca Popolare di Milano, Agenzia 24 - Milan, Italy Account holder: European School of Oncology Number: No IBAN: IT96G BIC: BPMIITMMXXX Reference: "Rare Tumours" + your name I authorise the European School of Oncology and any possible partner organisations in the event to use my personal data according to what is specified in Article 13 DLGS 196, available at or on request at fax number Signature Date ONLINE REGISTRATION AT

10 PRECEPTORSHIP REGISTRATION FORM 1 December 2018, Milan, Italy Please fill in this form and send it to raretumours@eso.net together with the registration form Family name First name Please choose ONE preceptorship for each of the following breakout slots. Breakout 1 ( h. 11:00/h. 13:00) Sarcomas Rare urogenital cancers Digestive rare cancers Breakout 2 ( h. 14:00/h. 16:00) Rare female genital cancers Rare thoracic cancers Rare skin tumors and uveal melanoma Breakout 3 ( h. 16:30/h. 18:30) CNS tumors Neuroendocrine tumors Head and neck cancers w/ Thyroid cancer